![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe PROMO |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Reprints |
Permissions |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
TUMOR IMMUNOLOGY
Minerva Biotecnologica 1999 December;11(4):303-9
Copyright © 1999 EDIZIONI MINERVA MEDICA
language: English
Monoclonal antibodies for diagnosis and prognosis of human tumors
Ménard S.
Molecular Targeting Unit, Department of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
Monoclonal antibodies (MAbs) that are reactive with tumor associated antigens have led to many of the recent advances made in tumor immunology. At present, many of these MAbs have already been used in various aspects of patient management and in better understanding the biology of carcinoma cell populations. Because of their diversity, specificity and biological activity, these MAbs are potentially ideal reagents for a variety of applications in malignant disorders such as clinical diagnosis using serum assays, immunocyto pathological analyses of effusions or fine-needle aspiration specimens, biopathological analysis of tumor specimens, immunoscintigraphy and radioimmunoguided surgery.